Asana BioSciences
Asana BioSciences announces dosing of first patient in Phase 1 trial of ASN004, a novel 5T4-Antibody-Drug-Conjugate
April 2022
Lawrenceville, N.J. April --, 2022 – Asana BioSciences, LLC, a clinical stage biopharmaceutical company, today announced that the first patient has been dosed in a Phase 1 trial for ASN004, an antibody drug conjugate (ADC) targeting the 5T4 oncofetal antigen (trophoblast glycoprotein), that is expressed in a wide range of malignant tumors but shows very limited expression in normal tissues. Higher 5T4 expression is associated with worse clinical outcome in non-small cell lung, head and neck, gastric, pancreatic, colorectal, and ovarian cancers.
Asana BioSciences to Present Additional Efficacy and Patient Reported Outcome Results from Phase 2b Study of Oral JAK/SYK Inhibitor Gusacitinib in Chronic Hand Eczema Patients in the Late-Breaking Session at the AAD Virtual Congress
April 2021
Lawrenceville, NJ, April 21, 2021 – Asana BioSciences, a clinical stage biopharmaceutical company, announced that it will present additional positive results from a Phase 2b study evaluating the efficacy and safety of its investigational oral Janus kinase family (JAK) and spleen tyrosine kinase (SYK) inhibitor gusacitinib (ASN002) in adult patients with moderate-to-severe chronic hand eczema (CHE) in a late- breaking research program at the American Academy of Dermatology Virtual Meeting (AAD VMX 2021), to be held April 23 – 25, 2021.
Asana BioSciences’ Gusacitinib Granted FDA Fast-Track Designation for Moderate-to-Severe Chronic Hand Eczema
February 2021
LAWRENCEVILLE, NJ, Feb 5, 2021 - (BUSINESS WIRE) - Asana BioSciences, a clinical stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast-Track designation to Asana’s gusacitinib (ASN002), an investigational oral, dual inhibitor of Janus Kinase (JAK) and Spleen Tyrosine Kinase (SYK), for the treatment of moderate-to-severe Chronic Hand Eczema (CHE).
Asana BioSciences to Present Clinical Data on Oral ASN007, A Novel ERK1/2 Inhibitor, at the 32nd EORTC-NCI-AACR Symposium
October 2020
Lawrenceville, NJ, October 20, 2020 – Asana BioSciences, a clinical stage biopharmaceutical company,
announced that ASN007 clinical data on safety, efficacy and pharmacokinetics in solid tumor patients
awill be presented at the 32 nd EORTC-NCI-AACR Virtual Symposium on Molecular Targets and Cancer
Therapeutics (ENA 2020) to be held on October 24-25, 2020. Details of this invited presentation are as
follows:
Asana BioSciences to Present Positive Results from Phase 2b Study of Oral JAK/SYK Inhibitor Gusacitinib in Patients with Chronic Hand Eczema in the Late-Breaking News Session at the EADV Virtual Congress
October 2020
Lawrenceville, NJ, October 20, 2020 – Asana BioSciences, a clinical stage biopharmaceutical company, announced that it will present positive results from a Phase 2b study evaluating the efficacy and safety of its investigational oral Janus kinase family (JAK) and spleen tyrosine kinase (SYK) inhibitor gusacitinib (ASN002) in adult patients with moderate-to-severe chronic hand eczema (CHE) in a late-breaking news session at the EADV Virtual Congress to be held October 29th-31st, 2020.
Asana BioSciences Announces Positive Topline Results from Phase 2b Study of Oral JAK/SYK Inhibitor Gusacitinib (ASN002) in Patients with Chronic Hand Eczema: Rapid and Significant Improvement Demonstrated
June 2020
Lawrenceville, NJ, June 2, 2020 – Asana BioSciences announced today positive topline results from a Phase 2b study evaluating the efficacy and safety of its investigational oral Janus kinase family (JAK) and spleen tyrosine kinase (SYK) inhibitor gusacitinib (ASN002) in 97 adult patients with moderate-to-severe chronic hand eczema (CHE). The study was a randomized, double-blind, placebo-controlled, parallel-group study evaluating oral gusacitinib (40 mg or 80 mg once daily) for up to 32 weeks, with the primary endpoint of mean modified total lesion severity score (mTLSS) at week 16 (NCT03728504).
Asana BioSciences Announces Topical Sodium Channel Blocker ASN008 Achieves Positive Results for the Treatment of Pruritus in Atopic Dermatitis; and Provides Update on JAK/SYK Inhibitor Gusacitinib in Phase 2 Studies for Chronic Hand Eczema and AD
March 2020
Lawrenceville, NJ, March 10, 2020 – Asana BioSciences announced today positive topline results from a Phase 1b study evaluating the treatment of pruritus associated with atopic dermatitis (NCT03798561) for its topical sodium channel blocker, ASN008. The Phase 1b double-blind, vehicle-controlled, dose escalation study randomized 25 adult patients with atopic dermatitis and a pruritus score of ≥7 using the Numerical Rating Scale (NRS) at baseline. Patients were randomized 3:1 receiving either ASN008 gel or vehicle gel applied topically either once or twice daily for 14 days.
Asana BioSciences to Present Phase 1 Clinical Safety and Efficacy Data of Oral, Once-Weekly, ASN007, a Novel ERK 1/2 Inhibitor, at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
October 2019
LAWRENCEVILLE, N.J, October 24, 2019 - Asana BioSciences, a clinical stage biopharmaceutical company, announced that it will present ASN007 data on clinical safety and efficacy in solid tumor patients at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference to be held in Boston, MA on October 26-30, 2019. The Scientific Committee selected the ASN007 late breaking abstract submission as one of the top ten abstracts for this year’s program and invited presentation as a short-talk.
Asana BioSciences Strengthens Leadership Team as ASN002 Phase 2b RADIANT Trial in Atopic Dermatitis Advances with a Second Positive DSMB Recommendation
February 2019
Lawrenceville, NJ, February 26, 2019 – Asana BioSciences, a clinical stage biopharmaceutical company focused on discovery and development of innovative medicines in immunology/inflammation and oncology, today announced the appointment of Shashank Mahashabde as Vice President of Chemistry, Manufacturing and Controls (CMC) and Pablo Jimenez, MD, FAPCR as Vice President and Therapeutic Area Head of Immunology.
Asana BioSciences to Present Correlation Between Microbiome Changes and Clinical Efficacy With JAK/SYK Inhibitor ASN002 in the Late-Breaking News Session at the American Academy of Dermatology (AAD) Annual Congress
February 2019
Lawrenceville, NJ, February 18, 2019 – Asana BioSciences, a clinical stage biopharmaceutical company, announced that it will present ASN002 data demonstrating changes in skin microbiome and correlation with clinical efficacy in patients with moderate-to-severe atopic dermatitis. These data will be presented in a late-breaking news session at the AAD Annual Congress in Washington, D.C. to be held March 1-5, 2019.
U.S. FDA Grants Fast Track Designation to Asana BioSciences’ Oral Dual JAK-SYK Inhibitor, ASN002, for the Treatment of Atopic Dermatitis
December 2018
LAWRENCEVILLE, N.J.--(BUSINESS WIRE, December 10, 2018) - Asana BioSciences, a clinical stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Asana’s investigational oral Janus Kinase (JAK) and Spleen Tyrosine Kinase (SYK) dual inhibitor ASN002 for the treatment of moderate-to-severe atopic dermatitis.
Asana BioSciences Announces Initiation of First-in-Human Clinical Study with ASN008, a Novel Topical Product for the Treatment of Pruritus Associated with Atopic Dermatitis
December 2018
Lawrenceville, NJ, December 20, 2018 - Asana BioSciences, a clinical stage biopharmaceutical company, announced today that it has been granted permission by the U.S. Food and Drug Administration (FDA) to start human clinical trials with ASN008, a topical gel for the treatment of pruritus (itch) associated with atopic dermatitis.
CEOCFO Magazine Conducts Interview with Dr. Sandeep Gupta, Founder, President and CEO of Asana BioSciences
October 2018
CEOCFO Magazine, October 29, 2018 - CEOCFO Magazine has published an interview that was conducted with Dr. Sandeep Gupta, Founder, President and CEO of Asana BioSciences, which is developing an oral JAK/SYK inhibitor for moderate-to-severe Atopic Dermatitis and targeted therapies for advanced metastatic cancers.
Asana BioSciences to Present Late-Breaking Clinical and Biomarker Data for Its JAK/SYK Inhibitor ASN002 at the European Academy of Dermatology and Venereology (EADV) Annual Congress
September 2018
LAWRENCEVILLE, N.J., September 10, 2018 - Asana BioSciences, a clinical stage biopharmaceutical company, announced that it will present ASN002 data demonstrating improvements in skin pathology, disease related genes and inflammation biomarkers, correlating with clinical efficacy, in patients with moderate-to-severe atopic dermatitis. These data will be presented in the late breaking news session at the EADV Annual Congress in Paris, France, to be held September 12-16, 2018.
Asana BioSciences Initiates Phase 2b Study of ASN002 in Patients with Moderate-to-Severe Atopic Dermatitis (RADIANT)
July 2018
Lawrenceville, N.J., July 19, 2018 – Asana BioSciences, a clinical stage biopharmaceutical company focused on discovery and development of novel targeted investigational medicines in Immunology/ Inflammation and Oncology, today announced initiation of a Phase 2b study of ASN002, an oral JAK/SYK inhibitor, in patients with moderate-to-severe atopic dermatitis (AD).
Asana BioSciences to Present Positive Clinical Efficacy and Skin Biomarker Data in Atopic Dermatitis Patients Treated with Its Novel Oral JAK/SYK Inhibitor, ASN002, at the International Investigative Dermatology Meeting
May 2018
Lawrenceville, N.J., May 8, 2018 – Asana BioSciences, a clinical stage biopharmaceutical company focused on development of novel treatments for autoimmune diseases and cancers, today announced that it will present efficacy and biomarker data from the clinical proof of concept study with ASN002, an oral, once-daily dual JAK/SYK inhibitor, in patients with moderate-to-severe atopic dermatitis at the International Eczema Council (IEC) meeting to be held in Orlando on May 16, 2018; and at the International Investigative Dermatology (IID) meeting in Orlando, May 16-19, 2018.
Asana BioSciences Announces Presentations of ASN003 (BRAF/PI3K inhibitor) and ASN007 (ERK1/2 inhibitor) at the American Association for Cancer Research Annual Meeting
April 2018
Lawrenceville, N.J., April 10, 2018 – Asana BioSciences, LLC, an oncology focused, clinical stage biopharmaceutical company, today announced that it will present updates for two of its lead molecules in clinical development at the American Association for Cancer Research (AACR) Annual Meeting being held in Chicago, IL, April 14-18, 2018. Download the full release for presentation details.
Asana BioSciences to Present Clinical Proof of Concept Study Results in Atopic Dermatitis with ASN002, A Novel Oral JAK/SYK Inhibitor, in the Late-Breaking Session at the American Association of Dermatology Annual Meeting
January 2018
Lawrenceville, N.J., January 31, 2018 – Asana BioSciences, a clinical stage biopharmaceutical company, today announced that it will present the clinical proof of concept study results with ASN002, an oral, once-daily dual JAK/SYK inhibitor, in patients with moderate-to-severe atopic dermatitis in the late-breaking session at the annual meeting of the American Association of Dermatology in San Diego to be held February 16 - 20, 2018. Download the full release for presentation details.
Asana BioSciences Announces Achievement of Positive Results in the Clinical Proof of Concept Study in Atopic Dermatitis with ASN002, A Novel Oral JAK/SYK Inhibitor
January 2018
Lawrenceville, N.J., January 4, 2018 – Asana BioSciences, a clinical stage biopharmaceutical company, today announced that ASN002, its oral, once daily dual JAK/SYK inhibitor, has achieved clinical efficacy in a proof of concept study in patients with moderate to severe atopic dermatitis. In a double blind, placebo controlled, dose-ranging, Phase 1b study conducted at multiple sites in the USA and Canada, ASN002 met the safety and efficacy endpoints after 4 weeks of treatment and was well tolerated.
Asana BioSciences Announces Acceptance of IND Application for Its Oral ERK1/2 Inhibitor
January 2018
Princeton, N.J., January 3, 2018 – Asana BioSciences, an oncology-focused, clinical stage biopharmaceutical company, today announced that the US FDA has accepted the IND application for ASN007, a potent and selective ERK1/2 inhibitor.
Asana BioSciences to Present Updates on its Oncology Development Pipeline at the
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 2017
Lawrenceville, N.J. October 24, 2017 – Asana BioSciences, LLC, an oncology focused, clinical stage biopharmaceutical company, today announced that it will present updates regarding three of its lead molecules at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics to be held in Philadelphia, PA, October 26-30, 2017.
Download the full release for more details.
Asana BioSciences presents pre-clinical data for ASN004, an antibody drug conjugate for the treatment of cancer, at the 5th Annual World ADC Summit
October 2014
Bridgewater, NJ (USA) October 27, 2014 – Asana BioSciences, LLC (“Asana”, www.asanabio.com), an independent member of the Amneal Alliance of Companies, today announced its participation in the 5th Annual World ADC Summit in San Diego, CA. Roger A. Smith, PhD, Vice-President at Asana BioSciences, presented preclinical data regarding the novel ADC ASN004 for the treatment of various cancers at the conference on October 27, 2014. Dr. Smith explained “ASN004 is a 5T4-oncofetal glycoprotein targeted antibody drug conjugate (ADC) developed in collaboration with Mersana Therapeutics, Inc. that selectively targets tumor cells and employs Fleximer® linker technology. ASN004 shows potent, selective antiproliferative activity in tumor cell lines, and causes complete tumor regression leading to tumor-free survivors in mouse models of human breast, gastric and other cancers. This novel ADC is efficacious at very low doses, well-tolerated and has successfully completed pilot toxicology assessments. ASN004 has the potential to be a very effective treatment for a wide range of cancers.